Immune‑related nephritis, ureteritis and cystitis secondary to immune checkpoint inhibitors: A case report and review of the literature
Open Access
- 8 June 2026
- journal article
- case report
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 32 (2) , 1-10
Abstract
Immune checkpoint inhibitors (ICIs) have beneficially impacted cancer therapy but are frequently associated with immune-related adverse events (irAEs), most commonly affecting the skin and gastrointestinal system. By contrast, genitourinary toxicities are rare and often underrecognized. The present case report outlines a 62-year-old male with metastatic colorectal cancer who developed pan-urinary tract irAEs (concurrent immune-related nephritis, ureteritis and cystitis) after exposure to three distinct classes of ICIs. The patient initially experienced pollakiuria, urinary urgency, dysuria and hematuria, which worsened after switching to cadonilimab and adebrelimab. This deterioration coincided with rising serum creatinine levels and lack of improvement with antibacterial treatment. Urinalysis revealed leukocyturia and hematuria, while imaging demonstrated bilateral hydroureteronephrosis and diffuse bladder wall thickening. A multidisciplinary evaluation led to the diagnosis of ICI-induced pan-urinary tract irAEs. Both urinary symptoms and renal function resolved rapidly after halting immunotherapy and starting glucocorticoid treatment, with no recurrence during follow-up. In addition, a comprehensive review of reported cases was conducted to characterize this rare irAE presentation and further propose both diagnostic criteria and management strategies to facilitate early detection and effective treatment.Keywords
This publication has 27 references indexed in Scilit:
- Clinical presentation of PD-1/PD-L1 immune checkpoint inhibitors induced cystitisInvestigational New Drugs, 2025
- Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trialThe Lancet, 2025
- Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trialThe Lancet Oncology, 2023
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximabIJU Case Reports, 2022
- CTCAE versión 5.0. Evaluación de la gravedad de los eventos adversos dermatológicos de las terapias antineoplásicasActas Dermo-Sifiliograficas, 2021
- A case of cystitis after administration of nivolumabInternational Cancer Conference Journal, 2017
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Amisulpride and symptomatic bradycardia: a case reportGeneral Hospital Psychiatry, 2015
- Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.The EMBO Journal, 1992